Xeris Biopharma Holdings, Inc.

NASDAQ:XERS

Biotechnology

Healthcare
$16.99 +0.58%

+$0.04 today

Market cap
$3.10B
Beta
0.90
P/E (TTM)
98.7
EPS (TTM)
$0.07
52W Low $4.40High $10.08

Volume 2.76M

Average 1.66M

XERS Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

Xeris Biopharma Holdings, Inc.NASDAQ: XERS

Gross Margin · Q1 FY2026 · quarter ended Mar 2026

Gross margin narrows to 84.0%

Gross margin was 84.0% in Q1 FY2026, down 1.5 pp from a year earlier. On a trailing-twelve-month basis it was 81.6%, up 0.6 pp year over year. Over 3 fiscal years it widened by 2.2 pp.

Context

  • Gross margin widened in 1 of the last 3 fiscal years.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
84.0%+6.3 pp QoQ
Last fiscal yearDec 2025
81.7%-0.2 pp YoY
LTMMar 2026
81.6%+0.6 pp YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-1.5 pp——
1 year-0.2 pp——
3 years+2.2 pp——
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2025
81.7%
Year-over-year change
-0.2pp

Gross Margin vs competitors

How XERS compares with its peers on the latest reported figures

  • XERS's LTM Mar 2026 gross margin of 81.6% is the 3rd highest of the 6 companies compared; the peer median is 79.9%.
  • Its year-over-year change of +0.6 pp is the 3rd highest of 6, against a peer median of -0.1 pp.
  • Over three fiscal years its change of +2.2 pp compares with a peer median of +4.2 pp.
XERS Competitors Peer median
Gross Margin for XERS and competitors
Company Period LTM level YoY 3-year change
CORTCorcept Therapeutics IncorporatedLTM Jun 202698.3% -0.1 pp-0.4 pp
ASNDAscendis Pharma A/SLTM Sep 202690.6% +3.8 pp+8.8 pp
XERSXeris Biopharma Holdings, Inc.LTM Mar 202681.6% +0.6 pp+2.2 pp
SEPNSepterna, Inc.LTM Sep 202679.9% -20.1 pp—
MNKDMannKind CorporationLTM Mar 202676.0% +1.3 pp+40.1 pp
ETONEton Pharmaceuticals, Inc.LTM Mar 202654.8% -3.7 pp-13.9 pp
MBXMBX Biosciences, Inc. Common StockFY2025— ——
GHRSGH Research PLCFY2025— ——
SPRBSpruce Biosciences, Inc.FY2025— ——
Peer median (excluding XERS) 79.9%-0.1 pp+4.2 pp

Competitors are the stored peer set for XERS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue49.59M110.25M163.91M203.07M291.85M
Cost of Revenue13.32M22.63M28.65M36.83M53.41M
Gross Profit36.27M87.61M135.27M166.24M238.43M
Gross Margin73.1%79.5%82.5%81.9%81.7%
Research & Development25.16M20.97M22.34M25.56M31.17M
Selling, General & Admin125.72M137.75M146.1M163.48M182.37M
Operating Expenses151.43M169.55M179.28M199.88M213.54M
Depreciation & Amortization1.88M12.67M13.16M12.63M12.16M
EBITDA(113.67M)(69.31M)(23.74M)(13.99M)12.71M
EBITDA Margin-229.2%-62.9%-14.5%-6.9%4.4%
Operating Income(115.16M)(81.94M)(44.01M)(33.65M)24.9M
Operating Margin-232.2%-74.3%-26.8%-16.6%8.5%
Interest Income313K2.58M4.75M5.32M4.74M
Interest Expense7.18M14.1M26.61M33.18M29.08M
Other Income / Expenses(7.57M)(14.14M)(19.49M)(23.46M)(24.34M)
Income Before Tax(122.73M)(96.08M)(63.5M)(57.1M)554K
Pre-Tax Margin-247.5%-87.2%-38.7%-28.1%0.2%
Income Tax Expense0(1.42M)(1.25M)(2.27M)0
Net Income(122.73M)(94.66M)(62.26M)(54.84M)554K
Net Margin-247.5%-85.9%-38.0%-27.0%0.2%
EPS (Basic)(1.55)(0.70)(0.45)(0.37)0.00
EPS (Diluted)(1.55)(0.70)(0.45)(0.37)0.00
Weighted Avg Shares79.03M135.63M137.67M146.77M160.43M
Weighted Avg Shares (Diluted)79.03M135.63M137.67M146.77M172.74M

Xeris Biopharma Holdings, Inc.

NASDAQ:XERS

Intrinsic Alpha fair value

Locked

Current Price

$16.99

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.